NLR Cancer Research Results

NLR, neutrophil-to-lymphocyte ratio (NLR): Click to Expand ⟱
Source:
Type: BioMarker

Neutrophil-to-lymphocyte ratio (NLR) is a calculated blood-based inflammatory biomarker obtained by dividing the absolute neutrophil count by the absolute lymphocyte count. It reflects the balance between systemic inflammation, represented partly by neutrophils, and lymphocyte-mediated immune activity.

In cancer, an elevated NLR is frequently associated with greater inflammatory burden, impaired antitumour immunity, more advanced disease, poorer treatment response, and reduced progression-free or overall survival. A decreased NLR is therefore generally considered the favourable direction, although its meaning depends on cancer type, disease stage, treatment, and the timing of measurement.

NLR is a nonspecific biomarker and may be altered by infection, corticosteroids, chemotherapy, granulocyte colony-stimulating factors, bone-marrow suppression, smoking, stress, and other inflammatory or medical conditions. There is no single universal cutoff value; thresholds commonly vary between approximately 3 and 5 across studies.

Calculation: absolute neutrophil count divided by absolute lymphocyte count.

Generally favourable cancer direction: decreased NLR. NLR should be classified as a hematologic biomarker or inflammatory index rather than as a direct molecular target.



Scientific Papers found: Click to Expand⟱
6750- DHA,  Chemo,    Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial
- Trial, BC, NA
*CD14↑, In the placebo group the proportion of T cells (CD3 +), and functionally active monocytes (CD14 + HLA-DR +) was reduced at the last cycle of chemotherapy (15 weeks) but remained constant in the DHA group
*NLR↓, The neutrophil-to-lymphocyte ratio (NLR) was maintained in the DHA group but increased in the placebo at the end of chemotherapy
eff↑, An increase in this ratio was associated with lower chance of achieving pathological complete response
*IL4↑, After 15 weeks of therapy, the DHA-supplemented group had higher concentrations of stimulated cytokines IL-4, IL-10, and the T helper type 1 cytokine IFN-γ after phytohemagglutinin (PHA) challenge, and higher concentrations of TNF-α and IFN-γ cytokin
*IL10↑,
*IFN-γ↑,
*TNF-α↑,
Imm↑, Supplementing DHA during breast cancer neoadjuvant chemotherapy improved systemic immune function by attenuating changes in blood cell concentrations, preventing depletion of immune cells
eff↑, Newell et al. [19] previously demonstrated an improvement in chemotherapy success, measured as reduced tumor weight and Ki67 activity (proliferation) in animals fed DHA (3.9% w/w of total fat) in combination with chemotherapy (docetaxel) i
TumW↓,


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Immune & Inflammatory Signaling(tgid=16) ⓘ

Imm↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 2,  

Functional Outcomes(tgid=23) ⓘ

TumW↓, 1,  
Total Targets: 3

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

NLR↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD14↑, 1,   IFN-γ↑, 1,   IL10↑, 1,   IL4↑, 1,   TNF-α↑, 1,  
Total Targets: 6

Scientific Paper Hit Count for: NLR, neutrophil-to-lymphocyte ratio (NLR)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1527  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page